H.C. Wainwright Reaffirms Their Buy Rating on Audentes Therapeutics (BOLD)

By Carrie Williams

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Audentes Therapeutics (BOLDResearch Report) today and set a price target of $48.00. The company’s shares closed last Monday at $27.08.

According to TipRanks.com, Chattopadhyay ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.5% and a 34.7% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences, and Sarepta Therapeutics.

Audentes Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $41.60, a 54.4% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $41.65 and a one-year low of $17.95. Currently, Audentes Therapeutics has an average volume of 403.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.